Skip to main content
. 2020 May 26;8(1):e000294. doi: 10.1136/jitc-2019-000294

Figure 5.

Figure 5

TIM-3 blockade shows no efficacy or synergy with vvDD in treating refractory lung cancer. (A) FACS assays showing increased pulmonary TIM-3+CD8+ T cells by vvDD treatment in urethane model. (B) FACS assays showing increased tumor-infiltrating TIM-3+CD8+ T cells but not TIM-3+CD4+ T cells by vvDD treatment in urethane model (n=5). (C) FACS assays showing further increased pulmonary TIM-3+CD8+ T cells but not TIM-3+CD4+ T cells by vvDD/PD-1 antibody combination treatment in urethane model (n=3). (D) FACS assays showing no changes in pulmonary LAG-3+ CD4+ and CD8+ T cells by vvDD treatment in urethane model. (E) FACS assays showing no significant changes in tumor-infiltrating LAG-3+CD4+ and LAG-3+CD8+ T cells by vvDD treatment in urethane model (n=4). (F) FACS assays showing no changes in pulmonary LAG-3+ CD4+ and CD8+ T cells by vvDD/PD-1 antibody combination treatment in urethane model (n=3). (G) Urethane model showing no efficacy of TIM-3 blockade alone in treating refractory lung cancer or enhancing vvDD therapy. (H) FACS assays showing no significant changes in CD4+ and CD8+ T-cell activation by TIM-3 antibody treatment in urethane model. (I) IHC showing no enhanced tumor cell apoptosis by TIM-3 antibody treatment in urethane model (n=9). Scale bar, 10 µm. (J) FACS assays showing increased PD-1 expression on CD4+ and CD8+ T cells by TIM-3 antibody treatment alone or together with vvDD in urethane model. FACS, fluorescent activated cell sorting; IHC, immunohistochemistry; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; ns, not significant; PD-1, programmed cell death 1; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; vvDD, vaccinia virus with double deletion.